Testing an investigational cream for atopic dermatitis or psoriasis skin
Tests an investigational cream on skin in people with atopic dermatitis or psoriasis.
Plain-language title generated from the registry record
Registry title: Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis
Key facts
- Where
- Osasco, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with mild atopic dermatitis (eczema) or mild to moderate psoriasis to test a skin cream used twice a day for 45 days.
- Age
- Atopic dermatitis group: 3 to 12 years or 18 to 50 years. Psoriasis group: 18 to 65 years.
- Sex
- Men and women can join.
- Disease stage
- Atopic dermatitis: active mild eczema with an EASI score between 7.1 and 9 points. Psoriasis: active mild to moderate disease with a PASI score between 1 and 15 points.
- Earlier treatment
- No systemic immunosuppressive or anti-inflammatory medicines or antihistamines in the 3 weeks before screening. No cosmetic or dermatological treatments in the 4 weeks before evaluation. Topical corticosteroids are allowed and will be recorded.
Main reasons for not taking part
- Pregnant or breastfeeding, or at risk of pregnancy, when applicable
- Weakened immune system from medicines or active disease
- Other skin problems in the assessed area that could affect the results
- History of allergy to cosmetic products
- Intense sun exposure in the 15 days before evaluation
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 65 years old?
Source: NCT07918560, who can take part
Where in Brazil
- Grupo MedcinOsasco, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brainfarma Industria Química e Farmacêutica S/A
- Trial code
- NCT07918560
- Record updated
- 5 November 2026
- Original description
The goal of this clinical trial is to evaluate the cosmetic efficacy and safety of an investigational cream in participants with atopic dermatitis or psoriasis. The main questions it aims to answer are:Read full original descriptionShow less
Evaluation of the Cosmetic Efficacy of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis: Clinical, Instrumental, and Subjective Study
The goal of this clinical trial is to evaluate the cosmetic efficacy and safety of an investigational cream in participants with atopic dermatitis or psoriasis. The main questions it aims to answer are:
Does the investigational cream improve skin condition and participant-reported outcomes after 30 and 45 days of use? Does the investigational cream improve clinical signs, skin hydration, skin barrier function, skin pH, and quality of life in participants with atopic dermatitis or psoriasis?
Participants will:
Apply the investigational cream twice daily for 45 days. Attend study visits at baseline, Day 30, and Day 45. Undergo clinical, instrumental, and subjective assessments. Complete questionnaires regarding quality of life and product perception. Undergo skin hydration, transepidermal water loss, and skin pH evaluations.
Inclusion: Male and female participants meeting one of the following age criteria:; Group I (Atopic Dermatitis): 3 to 12 years or 18 to 50 years of age; Group II (Psoriasis): 18 to 65 years of age; Group I: Clinical diagnosis of atopic dermatitis with active mild eczema at enrollment and an EASI score between 7.1 and 9 points; Group II: Clinical diagnosis of psoriasis with active disease at enrollment, classified as mild to moderate according to PASI, with a score between 1 and 15 points; Willingness and ability to comply with study procedures and attend all scheduled visits and assessments; Participant, parent, or legally authorized representative able to understand, provide informed consent, and sign the Informed Consent Form (ICF); For Group I, participants aged 7 years or older who are able to read and write must understand, provide assent, and sign the Assent Form.
Exclusion: Use of systemic immunosuppressive agents, systemic anti-inflammatory medications, or antihistamines within 3 weeks prior to screening; Use of topical corticosteroids for the management of atopic dermatitis or psoriasis is permitted and will be documented at enrollment, including active ingredient, concentration, frequency of use, and application site; Presence of concomitant dermatological disorders or active skin lesions in the assessment area that could interfere with interpretation of the study results, except for atopic dermatitis or psoriasis; Clinically relevant history or current evidence of alcohol or drug abuse; Known or suspected intolerance to products of the same category as the investigational product; Intense sun exposure within 15 days prior to evaluation; Cosmetic or dermatological treatments within 4 weeks prior to evaluation; Anticipated need to initiate or modify dermatological drug treatments during the study period; Skin conditions in the assessment area that may interfere with the evaluation of cutaneous reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn, except when associated with atopic dermatitis or psoriasis lesions; History of allergy to cosmetic products; Immunosuppression due to medication use or active disease; Uncontrolled endocrine disorders; Any other condition that, in the opinion of the investigator, would make participation in the study inappropriate; Pregnant or breastfeeding participants, or those at risk of pregnancy, when applicable.